Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Msx-122. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 known ✓ | P61073 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | FABP1 | P07148 | 1/20 | 0.54 |
| ▸ | FABP6 | P51161 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413125 | 0.90 | FABP1 (0.67) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL10055050 | 0.89 | CXCR4 (0.52) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL5206504 | 0.89 | MEN1 (0.54) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL4747480 | 0.89 | MEN1 (0.54) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL28475529 | 0.88 | FABP1 (0.64) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL10055016 | 0.87 | MAOA (0.58) | CXCR4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL10055030 | 0.85 | CXCR4 (0.89) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL13879818 | 0.85 | KDM4E (0.49) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL4066965 | 0.84 | MEN1 (0.50) | CXCR4ALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL14075931 | 0.84 | HDAC1 (0.51) | CXCR4ALDH1A1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| EP-4724503-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2026-04-15 | — | — | EP | claimed |
| US-20250360149-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS INC (KR) | 2025-11-27 | — | — | US | claimed |
| WO-2025202445-A2 | CXCR4 INHIBITOR COMPOUND IN THE TREATMENT AND/OR THE PREVENTION OF SEVERE ARDS | 4LIVING BIOTECH (FR) | 2025-10-02 | — | — | WO | claimed |
| EP-4536239-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2025-04-16 | — | — | EP | claimed |
| WO-2025059113-A1 | TREATMENTS FOR ENHANCING IMMUNE RESPONSE TO CLOSTRIDIOIDES DIFFICILE INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025050038-A2 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2025-03-06 | — | — | WO | claimed |
| CN-119562815-A | GPCR inhibitors and uses thereof | GPCR治疗公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2024254584-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS THROUGH INHIBITION OF CELL-IN-CELL PHENOMENON | INSTITUTE FOR CANCER RESEARCH d.b.a. THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024157207-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2024-08-02 | — | — | WO | claimed |
| US-20220184029-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROBLASTOMA | UNIV CHICAGO (US) | 2022-06-16 | — | — | US | claimed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | claimed |
| CN-104024217-B | Three rings for treating or preventing the symptom related to endocrine dysfunction contain amino-compound | 埃莫里大学 | 2017-09-15 | — | — | CN | claimed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | claimed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | claimed |
| US-9205085-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2015-12-08 | — | — | US | claimed |
| EP-2776387-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | Emory University (US) | 2014-09-17 | — | — | EP | claimed |
| US-20140248236-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY | 2014-09-04 | — | — | US | claimed |
| CN-104024217-A | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | UNIV EMORY | 2014-09-03 | — | — | CN | claimed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248236-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | CXCR4 4766/4885ALDH1A1 3626/4885MEN1 500/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | CXCR4 4766/4885ALDH1A1 3626/4885MEN1 500/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | CXCR4 4766/4885ALDH1A1 3626/4885MEN1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.